Transgene Enhances Scientific Advisory Board with New Appointments

Transgene, a biotech company specializing in virus-based immunotherapies for cancer, has announced the appointments of two prominent figures to its Scientific Advisory Board. Antoine Italiano and Ignacio Melero, both esteemed experts in cancer immunotherapy, join the board to bolster Transgene's scientific leadership. Their expertise is expected to expedite the development of Transgene's individualized neoantigen vaccines, myvac®, and other cancer vaccine candidates.

Prof. Antoine Italiano leads medicine at Institut Bergonié and is central to precision medicine efforts at Gustave Roussy. With extensive experience in clinical trials and over 500 publications, his contributions to precision oncology are notable. Meanwhile, Prof. Ignacio Melero, a pioneer in cancer immunotherapy from the University of Navarra, brings vast experience in cell-based and gene therapies.